Detalhe da pesquisa
1.
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
Blood
; 139(21): 3148-3158, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35303070
2.
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
Haematologica
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235512
3.
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study.
BMC Cancer
; 24(1): 124, 2024 Jan 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38267866
4.
Nomogram predictive models for adult patients with acute lymphoblastic leukaemia based on real-world treatment outcomes.
Ann Hematol
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38480542
5.
Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.
Ann Hematol
; 103(4): 1211-1220, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38409598
6.
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Am J Hematol
; 99(4): 774-779, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38343062
7.
When is the best time and grade to start ruxolitinib in corticosteroid-refractory acute graft-versus-host-disease: A multi-center research.
Clin Transplant
; 38(1): e15195, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37987525
8.
Emodin derivative E35 and its combination with autophagy inhibitor against acute myeloid leukemia cells in vitro and in vivo.
Exp Cell Res
; 432(2): 113780, 2023 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37742725
9.
Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).
Proc Natl Acad Sci U S A
; 118(6)2021 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33495363
10.
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
Invest New Drugs
; 41(4): 606-616, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37420136
11.
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.
BMC Cancer
; 23(1): 980, 2023 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37838670
12.
Differentiation and prognostic stratification of acute myeloid leukemia by serum-based spectroscopy coupling with metabolic fingerprints.
FASEB J
; 36(7): e22416, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35713583
13.
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
Am J Hematol
; 98(4): 571-579, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36683422
14.
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Am J Hematol
; 98(11): 1742-1750, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647123
15.
Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms.
Acta Haematol
; 146(4): 293-306, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36812897
16.
Safety and performance of the Spectra Optia apheresis system for white blood cell depletion in patients with elevated white blood cell counts.
J Clin Apher
; 38(4): 396-405, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36655281
17.
Physicians' knowledge of invasive fungal disease in China.
Mycoses
; 66(8): 723-731, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37059587
18.
Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 study.
Int J Cancer
; 150(6): 984-992, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34674396
19.
Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial.
Invest New Drugs
; 40(2): 349-360, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35031896
20.
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.
Hematol Oncol
; 40(5): 930-940, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35858181